A61K 40/4205
Her-2/neu/erbb2, her-3/erbb3 or her 4/ erbb4
Official title: {Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ ErbB4}
A61K40/4205 (Her-2/neu/erbb2, her-3/erbb3 or her 4/ erbb4) appears on 289 US grants and 723 published applications in this corpus.
Search patents in A61K- Granted patents
- 289
- Published applications
- 723
- Assignees
- 316
- Inventors
- 1,235
- Latest grant
- 29 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1998 | 3 | 0 |
| 1999 | 1 | 0 |
| 2000 | 1 | 0 |
| 2001 | 0 | 0 |
| 2002 | 0 | 7 |
| 2003 | 2 | 4 |
| 2004 | 0 | 4 |
| 2005 | 0 | 4 |
| 2006 | 2 | 3 |
| 2007 | 1 | 0 |
| 2008 | 2 | 6 |
| 2009 | 1 | 4 |
| 2010 | 6 | 7 |
| 2011 | 3 | 7 |
| 2012 | 5 | 6 |
| 2013 | 0 | 9 |
| 2014 | 4 | 11 |
| 2015 | 5 | 10 |
| 2016 | 9 | 17 |
| 2017 | 6 | 35 |
| 2018 | 11 | 32 |
| 2019 | 5 | 36 |
| 2020 | 18 | 59 |
| 2021 | 26 | 67 |
| 2022 | 46 | 98 |
| 2023 | 31 | 81 |
| 2024 | 32 | 93 |
| 2025 | 40 | 72 |
| 2026 | 29 | 51 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Methods of activating cells via PTP 1B inhibition29 Sep 2026US 12,746,285 B2Monash University
- Genetically engineered phagocytes, and related compositions, vectors, methods and systems22 Sep 2026US 12,741,025 B2The Regents of the University of California
- Chimeric antigen receptors to HER2 and methods of use thereof22 Sep 2026US 12,742,020 B2BioAtla, Inc.
- Diverse antigen binding domains, novel platforms and other enhancements for cellular therapy22 Sep 2026US 12,742,152 B2Angeles Therapeutics, Inc.
- Compositions and methods for inhibiting T cell exhaustion8 Sep 2026US 12,729,245 B2The Board of Trustees of the Leland Stanford Junior University
- Chimeric Cytokine Receptors and Methods of Use8 Oct 2026US 2026/0308235 A1
- Small Molecule Based Method Of Modifying T Cells8 Oct 2026US 2026/0308520 A1Agency for Science, Technology and Research
- T-cell receptors targeting her2 and methods of use thereof1 Oct 2026US 2026/0297158 A1Board of Regents, The University of Texas System
- Coreceptor chimeric antigen receptor24 Sep 2026US 2026/0284111 A1
- Targeted lnp compositions for in vivo immune cell engineering and methods of use thereof17 Sep 2026US 2026/0274918 A1CREATE Medicines, Inc.
Most cited
By later US patents
- Chimeric receptor genes and cells transformed therewith327US 7,741,465 B12010
- Chimeric receptor genes and cells transformed therewith196US 8,211,422 B2The United States of America, as represented by the Secretary, Department of Health and Human Services · 2012
- Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated114US 5,801,005 AUniversity of Washington · 1998
- T cell modifying compounds and uses thereof108US 9,597,357 B2Sangamo BioSciences, Inc. · 2017
- Compositions, methods, and computer systems related to making and administering modified T cells107US 9,499,855 B2Elwha LLC · 2016